Enzalutamide Treatment in COVID-19
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Corona Virus Infection
- COVID-19
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: Prospective, randomized (2:1), open, multicentre, clinical controlled trialMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 50 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04475601
- Collaborators
- Sahlgrenska University Hospital, Sweden
- Umeå University
- University Hospital, Umeå
- Uppsala University Hospital
- Skane University Hospital
- Jonkoping County Hospital
- Sundsvall Hospital
- Helsingborgs Hospital
- Göteborg University
- Astellas Pharma Europe Ltd.
- Norrlands University Hospital
- Investigators
- Principal Investigator: Andreas Josefsson, MdPhD Norrlands University Hospital, Region Västerbotten